Syndax Pharmaceuticals Balance Sheet
NASDAQ: SNDXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Syndax Pharmaceuticals financial position
At the end of fiscal 2025, Syndax Pharmaceuticals reported total assets of $529.7 million, down 26.9% from a year earlier against total liabilities of $465.1 million. Shareholders' equity stood at $64.6 million, or 12.2% of assets. The company held $134.9 million in cash and equivalents against $343.9 million of debt, a net debt position of $209.0 million.
The current ratio (current assets divided by current liabilities) was 4.40, meaning short-term assets cover obligations due within a year. Debt-to-equity was 5.32.
Summary generated from market data by MetaCap's automated system. Methodology
Syndax Pharmaceuticals balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 134.93M | 154.08M | 295.39M | 74.36M | 221.97M | 115.24M | 24.61M | 33.77M | 35.17M | 23.84M |
| Short-Term Investments | 259.14M | 418.80M | 275.30M | 401.45M | 217.97M | 177.82M | 35.17M | 47.14M | 94.81M | 81.49M |
| Receivables | 38.00M | 7.60M | 0 | — | — | — | — | — | — | — |
| Inventory | 32.75M | 366.00K | 0 | — | — | — | — | — | — | — |
| Total Current Assets | 528.08M | 603.06M | 580.88M | 489.79M | 448.40M | 298.86M | 62.33M | 83.35M | 133.44M | 108.51M |
| Property, Plant & Equipment | 181.00K | 0 | 8.00K | 20.00K | 278.00K | 192.00K | 281.00K | 373.00K | 267.00K | 260.00K |
| Long-Term Investments | 0 | 119.52M | 29.83M | 5.47M | 0 | — | — | — | 3.25M | — |
| Total Assets | 529.71M | 724.82M | 612.88M | 497.24M | 449.66M | 300.61M | 63.52M | 83.94M | 137.19M | 109.01M |
| Accounts Payable | 16.58M | 11.63M | 9.96M | 4.35M | 5.67M | 3.51M | 6.18M | 1.44M | 2.23M | 2.38M |
| Short-Term Debt | 343.91M | 343.68M | 0 | — | — | — | — | — | — | — |
| Total Current Liabilities | 120.12M | 103.55M | 58.10M | 29.07M | 20.68M | 18.87M | 18.37M | 16.11M | 15.80M | 10.37M |
| Long-Term Debt | — | 331.56M | 0 | — | — | — | — | — | — | — |
| Total Liabilities | 465.08M | 436.69M | 58.68M | 29.79M | 41.29M | 48.42M | 31.93M | 30.89M | 32.87M | 24.87M |
| Shareholders' Equity | 64.63M | 288.12M | 554.20M | 467.45M | 408.37M | 252.19M | 31.60M | 53.05M | 104.32M | 84.14M |
| Retained Earnings | -1.51B | -1.22B | -902.40M | -693.04M | -543.70M | -568.63M | -495.47M | -439.42M | -366.11M | -305.29M |
| Total Debt | 343.91M | 675.25M | 0 | — | — | — | — | — | — | — |
| Net Cash (Debt) | 50.16M | -102.36M | 570.70M | 475.80M | 439.94M | 293.06M | 59.77M | 80.91M | 129.97M | 105.33M |
| Shares Outstanding | 87.41M | 85.69M | 84.83M | 68.11M | 54.98M | 47.88M | 27.14M | 24.84M | 24.39M | 18.22M |
This table shows 10 annual periods of Syndax Pharmaceuticals's balance sheet, from FY 2025 back to FY 2016, across 18 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow SNDX's reporting calendar. What is a balance sheet?